首页> 外文OA文献 >A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy

【2h】

A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy

机译：氟斯特语500mg的II期研究作为急性受体阳性，人体表皮生长因子受体2阴性晚期化疗后晚期乳腺癌患者的维持治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Fei Xu; Qiufan Zheng; Wen Xia; Quchang Ouyang; Danmei Pang; Zhongyu Yuan; Yanxia Shi; Roujun Peng; Qianyi Lu; Shusen Wang;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy [J] . Fei Xu, Shusen Wang, Qiufan Zheng, The oncologist . 2021,第5期

机译：氟斯特朗500mg作为维持治疗在激素受体阳性，人体表皮生长因子受体2阴性晚期化疗后晚期乳腺癌患者治疗治疗
2. A PHASE II STUDY OF METRONOMIC DAILY ORAL VINORELBINE AS FIRST-LINE CHEMOTHERAPY IN ADVANCED/METASTATIC HORMONE RECEPTOR POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) BREAST CANCER RESISTANT TO ENDOCRINE THERAPY: VINOMETRO [J] . Thomssen Christoph, Decker Thomas, Fehm Tanja, The Breast : . 2017,第Suppla1期

机译：II研究对群体每日口服血红素的研究，作为先进/转移激素受体的一线化疗阳性（HR加）/人表皮生长因子受体2阴性（HER2-）乳腺癌对内分泌治疗：VINOFORGRO
3. A PHASE II STUDY OF METRONOMIC DAILY ORAL VINORELBINE AS FIRST-LINE CHEMOTHERAPY IN ADVANCED/METASTATIC HORMONE RECEPTOR POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) BREAST CANCER RESISTANT TO ENDOCRINE THERAPY: VINOMETRO [J] . Thomssen Christoph, Decker Thomas, Fehm Tanja, The Breast : . 2017,第Suppla1期

机译：II研究对群体每日口服血红素的研究，作为先进/转移激素受体的一线化疗阳性（HR加）/人表皮生长因子受体2阴性（HER2-）乳腺癌对内分泌治疗：VINOFORGRO
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients [O] . Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, 2017

机译：PALOMA-3：在有激素受体阳性人类表皮生长因子受体2阴性的绝经前和绝经后妇女中使用或不使用帕博西利的氟维西汀的III期试验已在先前的内分泌治疗中进展阴性转移性乳腺癌—亚洲患者的安全性和有效性
7. PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients [O] . Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, 2017

机译：paLOma-3：氟维司群有或没有palbociclib的绝经前和绝经后妇女的III期试验激素受体阳性，人类表皮生长因子受体2 - 先前内分泌治疗进展的阴性转移性乳腺癌 - 亚洲患者的安全性和有效性

A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy

著录项

引文网络

相似文献

相关主题

期刊订阅